Exscientia announces second molecule created using AI from Sumitomo Dainippon Pharma collaboration to enter Phase 1 clinical trial

Exscientia Receives Queen’s Award for Enterprise in Innovation

Exscientia announces investment of up to $525M

AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy 

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia completes $100 million Series C financing round with BlackRock funds

Exscientia in FT1000 and tops Alantra Global

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Exscientia appoints leading financier Elizabeth Crain to the Board of Directors

"All drugs will be designed with AI by decade's end"; Daily Telegraph Profile talking to Andrew Hopkins.

Forbes Coverage of Exscientia's Gates $4.2M collaboration

Exscientia appoints Richard Law to expand its AI-drug discovery partnering business 

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion.

Exscientia applies Genome scale AI-Drug Discovery to critical global health challenges - 
Company receives $4.2M grant from Bill & Melinda Gates Foundation to identify new targets and leads for malaria, tuberculosis, and non-hormonal contraception

Exscientia appoints biopharma investment banker and executive Ben Taylor as Chief Financial Officer

Exscientia  recruits  industry  innovator
Garry  Pairaudeau  as  Chief  Technology  Officer



Exscientia and Blue Oak Pharmaceuticals announce collaboration to rapidly discover innovative treatments for CNS disorders

Exscientia appoints industry R&D veteran, David Nicholson, as Chairman as company extends pipeline 

Huadong Medicine and Exscientia enter co-development partnership to accelerate oncology drug discovery through artificial intelligence 

Exscientia Featured in TECH TRACK 100 report on Britain's Fastest Growing Tech Companies

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Exscientia raises $60 million in Series C financing round led by Novo Holdings

SRI International and Exscientia Enter Collaboration to Accelerate Drug Discovery Through Automation and Artificial Intelligence

Exscientia to screen nearly every known approved and investigational drug - 15,000 clinical molecules - against key COVID-19 drug targets to progress rapid treatments and generate data to seed design of superior molecules 

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research 

The Guardian focuses on Exscientia's screen of 15,000 drugs in search for a coronavirus treatment

Bloomberg Article covering Artificial Intelligence and Coronavirus

Coverage of our company in Financial Times newspaper

Financial Times : 

Read the article detailing Exscientia's work on the first AI-designed drug 
to enter clinical trials.

Sumitomo Dainippon Pharma and Exscientia Joint Development  New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial

BBC coverage of Artificial intelligence-created medicine to be used on humans for first time

Exscientia appoints Dr. David Hallett as Chief Operating Officer

Exscientia appoints Dr. David Hallett as Chief Operating Officer as company positions for further growth

AI Design of new therapeutics for cardiovascular and oncology disease

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery

AI Design enables new bispecific small molecule modality

Sanofi Exercises option on Exscientia-designed bispecific small molecule for treatment of immunological conditions

Joint venture will initiate drug discovery programs targeting rare diseases using AI

Exscientia enters broad rare disease drug discovery collaboration with Rallybio

Firm enters a multi-target AI drug discovery partnership with initial focus on oncology

Exscientia expands international collaborations with Shanghai-headquartered GT Apeiron Therapeutics

Exscientia achieves molecule discovery milestone as part of GSK collaboration 

Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia

Exscientia がアジアの創薬マーケットを狙った子会社を日本に設立

Celgene and Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity

Exscientia to receive up to CHF 67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche

Exscientia initiates sixth AI drug discovery partnership

NEW INVESTORS CELGENE CORPORATION AND GT HEALTHCARE CAPITAL PARTNERS JOIN SERIES A INVESTOR EVOTEC.

Exscientia raises US $26 million in series B financing round to accelerate scaling as the leading AI drug discovery company

Exscientia builds "full stack" AI-driven drug discovery capabilities through acquisition of kinetic discovery

Facilities in the Schrödinger Building to bring together AI experts and biologists

Leading AI-driven drug discovery company Exscientia expands to the Oxford Science Park

Exscientia appoints Georgy Egerov as chief financial officer bringing significant capital markets and strategic development expertise to support business growth

Exscientia to present at Numis T500 conference 2018 - linking innovative companies with investors

Publication including Exscientia's chief chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia appoints Alex Snow, founder of Oxford innovation sciences and former CEO of Lansdowne Partners, as deputy chairman

Exscientia opens new office in Oxford as part of plan for rapid growth and expansion

Exscientia wins science and technology business of the year

Exscientia wins best emerging biotech company award at OBN Annual Awards 2017

Evotec invests in Exscientia to advance AI-driven drug discovery

GSKが指定する最大10の創薬標的タンパク質に絞った前臨床創薬共同研究

EXSCIENTIAはGSKと戦略的共同研究契約を締結

Pre-clinical collaboration focused on up to 10 targets nominated by GSK

Exscientia enters strategic drug discovery collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is delighted to announce that its Chief Executive Officer Andrew Hopkins has been named Chemistry World ‘Entrepreneur of the Year’. Chief Technology Officer Jérémy Besnard also won the ‘Rising Star in Industry’ Award at the Chemistry Means Business 2017 Awards, hosted by the UK Royal Society of Chemistry in Manchester this week.

Exscientia wins two awards at Royal Society of Chemistry's 'Chemistry Means Business' Awards 2017

Initiates collaboration to develop bispecific-small-molecule drugs

Exscientia announces EUR250 million collaboration for a multiple-product development and licence option agreement with Sanofi

二重特異性低分子薬剤の共同研究開発を開始

エクセンシアが複数製品開発およびライセンスオプション契約で サノフィとの2億5000万ユーロの提携を発表

Exscientia announces progress in immuno-oncology collaboration with Evotec presented at AACR

Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics

Exscientia names young business of the year

Exscientia one of three finalists for best emerging UK biotech company at the OBN Awards

Exscientia Ltd, reaches first delivery milestone in collaboration with Sumitomo Dainippon Pharma Co., Ltd.

Exscientia CEO Andrew Hopkins wins prestigious BBSRC innovator award

Andrew Hopkins, CEO of Exscientia, is awarded Scottish Enterprise Life Science Business prize

Exscientia partners with Sunovion Pharmaceuticals inc. to research new medicines for psychiatric disorders.

Recruitment of Andy Bell, co-inventor of Sildenafil, to head up Exscientia chemistry team

Bispecific drug discovery agreement with Sumitomo Dainippon Pharma Co., Ltd

BBSRC chief executive Douglas Kell highlights Exscientia approach for advancement of complex drug design

Exscientia strengthens drug design capability with key appointments

Exscientia establishes collaboration with Janssen research & development

Bi-specific enzyme inhibitors deal with top 10 US pharma

Exscientia signs proof-of-concept deal with Sunovion Inc. to discover 'bi-specific' compounts for psychiatric disease

Meet the Exscientia team of world-class scientists and leading pharmatech experts. We are driven by a passion for changing the world. Visit our site to discover more.

Meet The Team | Our World-Class Scientists | Exscientia

Our world-class scientists and leading pharmatech experts are driven by a passion for changing the way medicines are discovered. Find out more our team below.

Responsible for developing over 25 new drug products in his career, David brings a wealth of drug hunting experience to Exscientia’s board. He has held a number of senior leadership positions over a 40-year career in research and development at Allergan, Bayer, Merck, Schering-Plough and Organon. Dr Nicholson brings a wealth of experience having previously championed the breakthrough anti-PD1 cancer drug Keytruda® (pembrolizumab) all the way from its earliest research and into development, heralding a revolution in cancer therapy.

Andrew is one of the most distinguished and cited scientists in modern drug discovery. As part of his role as founder and CEO of Exscientia, he invented and championed an automated and algorithmic approach to drug design and drug discovery. Prior to that, he spent 14 years at Pfizer and in academia, pioneering cutting-edge projects using data mining and machine learning in the pharmaceutical industry. His papers, published in Nature journals, are widely considered as pivotal points in the new paradigm of modern drug discovery.

Ben joins Exscientia with more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays in the U.S., Asia, and Europe. During this period, Ben focused on financing, strategic and cross-border transactions in the biopharmaceutical industry. Ben served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology focused biotechnology company, where he oversaw the company’s advancement from Phase 1 to Phase 3. Prior to joining Exscientia, Ben was interim CFO at Aetion, a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation.

Mario is a Member of the Supervisory Board of drug discovery and development company, Evotec. He has extensive experience as a Non-Executive Director within the healthcare industry, having also held positions at Forge Therapeutics and Pharminox. Prior to that, he served as Chief Operating Officer at Evotec and was a Founding Chemist of Oxford Asymmetry International. He received a doctorate in mechanistic organometallic chemistry from the University of Oxford before continuing there with post doctoral studies on aspects of the biosynthesis of penicillins.

Robert currently leads the Novo Holdings Principal Investment team, with responsibility over Growth Equity investments.
Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.
Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.

Elizabeth has over 30 years’ experience in banking, investment and operating roles and has been  named one of the "25 Most Powerful Women in Finance" by American Banker magazine. After 20 years at U.S. and European  investment banks, Elizabeth became one of the  founding partners of Moelis & Company and led the firm’s IPO. She also serves in trustee or advisory positions for The Wharton School, The Royal Academy Trust and the Global Futures Council of the World Economic Forum. 

Andrew is one of the most distinguished and cited scientists in modern drug discovery. As part of his role as founder and CEO of Exscientia, he invented and championed an automated and algorithmic approach to drug design and drug discovery. 

Prior to that, he spent 14 years at Pfizer and in academia, pioneering cutting-edge projects using data mining and machine learning in the pharmaceutical industry. 

His papers, published in Nature journals, are widely considered as pivotal points in the new paradigm of modern drug discovery.

Ben joins Exscientia with more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays in the U.S., Asia, and Europe. During this period, Ben focused on financing, strategic and cross-border transactions in the biopharmaceutical industry. 

Ben served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology focused biotechnology company, where he oversaw the company’s advancement from Phase 1 to Phase 3. 

Prior to joining Exscientia, Ben was interim CFO at Aetion, a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation.

Dave is an experienced drug hunter with over 20 years’ experience leading successful teams and driving major strategic collaborations.  Prior to joining Exscientia he held various positions within Evotec including EVP Chemistry and more recently EVP Alliance Management.  Earlier, he spent almost 10 years working for Merck at their former neuroscience facility near Cambridge.  A medicinal chemist by training, Dave was educated at Cambridge before obtaining a PhD at the University of Manchester, followed by post-doctoral studies at the University of Texas at Austin.

Mark spent seven years working in Japan at the Protein Engineering Research institute in Osaka, Yamanouchi Pharmaceutical Co. Ltd. (now Astellas) and Helix Research Institute. Upon returning to the UK, he worked at Inpharmatica Ltd., a biotechnology company focusing on knowledge-based drug discovery founded by Dame Professor Janet Thornton FRS.

Garry joined Exscientia following an impactful career at AstraZeneca where he combined drug hunting and technology leadership.  In his role as Vice President of Hit Discovery and Chair of the Global Chemistry Leaders Network he led High throughput Screening, DNA Encoded Library screening and virtual screening, he was also responsible for many strategic initiatives; Garry championed AstraZeneca’s developments in artificial intelligence, machine learning and physics based computational methods, ultimately leading to AstraZeneca's “Augmented Drug Design” programme. He also established an automation facility in Gothenburg, dedicated to synthesis and integrated screening.   He has a passion for efficient drug discovery and constantly strives for new, innovative ways to drive projects forward to discover high quality candidates. Garry obtained his PhD in organic Chemistry from the University of Southampton.

Richard has spent almost 20 years in drug discovery, first as a computational chemist, and then in business development. After his degree and PhD in Biochemistry & Molecular Biophysics at the University of Oxford, he spent several years working in academia, biotech and government labs in California as a comp chemist. In 2008 he was hired as the Head of Computational Chemistry at Evotec, and after leading a team and several drug discovery projects, became SVP Business Development, managing a team to build successful alliances between Evotec and biotech and Pharma.

Richard completed his PhD at the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci. Prior to that, he was a Senior Scientist at Inpharmatica, a London-based biotech for five years. In 2012, after joining the University of Dundee, Richard received the College of Life Sciences Innovator of the Year Award.

After a degree in chemistry at Imperial College, Richard worked in various scientific research and consultancy roles at Thomson Scientific, Inpharmatica and Biovia (now Dassault Systèmes).

Jérémy is a co-inventor of the original Exscientia technology for the Automated Design of ligands to Polypharmacological Profiles, which was developed during his PhD and published in Nature. Jérémy graduated with a French Diplôme d’Ingénieur Chimiste from Ecole Nationale Superieure de Chimie de Montpellier and gained a MSc in Chemical Biology from the University of Montpellier II in 2008.

Adrian is an interdisciplinary researcher with a broad background in computational approaches to drug discovery. He also holds a PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci.

Anthony joined Exscientia from OxXChem, a University of Oxford project to develop the tools and culture needed for successful hit-to-lead in fragment-based drug discovery. Prior to that, he was a Postdoctoral Research Fellow at the University of California. His PhD focused on developing computational tools to aid in drug design and lead development, which he completed while working at GSK.

Andy is one of the world’s leading medicinal chemists. He is a co-inventor of Sildenafil and a contributor to the development of Voriconazole. These medicines have generated sales of nearly $40 billion. Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society in recognition for his contributions to medicinal chemistry.

Prior to joining Exscientia, Andrew was Senior Group Leader of the Primary Pharmacology Group at global biopharmaceutical company, UCB. While there, he oversaw a team of cellular and molecular pharmacologists responsible for conceiving and delivering complex cellular assays to support small molecule and biological drug discovery. Before that, he spent time in leadership positions at both Oxford Glycosciences and Prolifix. He has a PhD in anti fungal discovery from the University of Bristol. 

Thorsten gained his PhD in organic chemistry from Cambridge University working with Prof. Ian Paterson. He then moved to AstraZeneca where he learned the craft of Medicinal Chemistry working for 16 years on projects covering the full spectrum of drug discovery from target to candidate selection. His passion for science led him to work on emerging technologies. This resulted in a move the C4X Discovery which he supported during the transition from a technology platform to a biotechnology SME in a number of roles. 

Daniel is a bioinformatician with 20 years’ industry experience in Research and Translational informatics. After gaining his D. Phil from Oxford University, he spent nine years at GSK. He then moved to Wyeth to help establish the Translational Medicine Research Collaboration and has recently spent six years in Frankfurt as a department head for Sanofi.

Iva is at the forefront of some of Exscientia’s most challenging and rewarding research, combining this role with her position as an Independent Investigator at the University of Dundee. Prior to joining, she served as Chief Scientific Officer at Kinetic Discovery and as Principal Scientist at Pfizer. She also completed a PhD in biochemistry at Masarykova Univerzita.

Ben brings a wealth of industry experience, having joined Exscientia from BenevolentAI where he was the company’s Financial Planning and Analysis Lead. Prior to that, he spent four years in the finance team at Immunocore, a leading biotechnology company focused on delivering first-in-class biological therapies.

Before joining Exscientia Dan worked in senior legal roles in UK and US listed life science and biotech companies. Dan qualified as a solicitor at Allen & Overy and has worked in top-tier private practice in London, Tokyo, Sydney, and Madrid. He has a degree in Modern Languages and Cultures from Durham University.

Chris joins us from the prestigious Saïd Business School at Oxford University, where as Head of HR he led the HR Operations and Wellbeing teams. He was awarded his MA in HR from Oxford Brookes University. Chris is interested in the application of automation and tech to deliver innovative ways to improve the employee experience in an open, collaborative style. 

Having gained a PhD in neuroscience from the University of Cambridge, Milly subsequently stepped into the world of commercial strategy, which she now leads at Exscientia. Prior to that, she spent time as a Director at Huron Management Consulting and as a Consultant in Global Pricing and Market Access for Evidera, a leading global contract research organisation within pharmaceutical product development. 

Executive Director of Corporate Development

Mima provides a wide range of support to the Exscientia Executive Team. Prior to joining the company, she spent a number of years in the hospitality and events industry, working as Front Office Manager at the Old Bank Hotel, Senior Meetings and Events Coordinator at the Four Pillars Hotel and Senior Assistant Manager at Vanbrugh House Hotel.

Alastair completed his PhD in Pharmacology at Imperial College, London, under the supervision of Professor Sir Magdi Yacoub FRS. He subsequently worked as a developer at Organon/Merck where he developed solutions to automate in-vitro compound testing and analysis. Following this Alastair took a position as  Informatics Manager for the Drug Discovery Unit at the University of Dundee, managing all data activities of the drug discovery process whilst  successfully completing a MSc in Data Science.   

Alex is an experienced investor, banker and entrepreneur, having previously founded Oxford Sciences Innovation (OSI) and raised more than £600 million to commercialise world-leading science originating at Oxford University. Prior to that, he spent 20 years in investment banking and fund management, including serving as CEO of hedge fund, Lansdowne Partners, and as founder and CEO of Evolution Group, a UK investment banking and securities firm that was sold to Investec Bank for £232 million in 2011.

Alice is a GPCR pharmacologist having completed her PhD under the supervision of Chris Langmead and Arthur Christopoulos at Monash University in Australia as well as Andrew Lawrence from the Florey Institute in Melbourne, Australia. She also took a postdoctoral position at the Institute of Functional Genomics in Montpellier, France before joining the team at Exscientia.

Amy studied Zoology at the University of Aberdeen and completed an MPhil. in Biology at the University of Nottingham.  Bringing a wealth of experience working as a laboratory technician in academia and industry, she is responsible for maintaining the smooth running of the laboratories at Exscientia.

Andrew is one of the most distinguished and cited scientists in modern drug discovery. As part of his role as founder and CEO of Exscientia, he invented and championed an automated and algorithmic approach to drug design and drug discovery. Prior to that, he spent 14 years at Pfizer and in academia, pioneering cutting-edge projects using data mining and machine learning in the pharmaceutical industry. His papers, published in Nature journals, are widely considered as pivotal points in the new paradigm of modern drug discovery.  

Angeline studied Biochemistry at the University of Paul Sabatier in Toulouse, France followed by an MSc in Applied Biomolecular Technology at the University of Nottingham. Most recently she worked on protein production for  the study of DNA repair proteins at Structural Genomics Consortium.

Alongside her role at Exscientia, Aude serves as Honorary Lecturer-Group Leader at the University of Leicester, focusing on the structural biology of cancer-related targets. Prior to that, she spent time as a Scientific Coordinator at the Structural Genomics Consortium and as Lecturer-Group Leader at the University of Montpellier. She completed her PhD at the University of Warwick.

Before joining Exscientia, Bill worked for four years in the Computational Chemistry and Chemoinformatics department of biotechnology company, Sygnature Discovery. He completed a PhD at the University of Ioannina before spending time as an Adjunct Lecturer at the University of West Macedonia and Postdoctoral Researcher at the University of Évry Val d'Essonne. 

Cara is Exscientia’s Talent Acquisition Manager responsible for the overall hiring strategy and recruitment drive. Prior to joining Cara was an Executive Search Leader experienced in hiring global top talent in Life Sciences across multiple markets. Cara has strong exposure to business growth and scale having built the UK Board and C-Level Drug Discovery network in her former role.

Prior to joining Exscientia, Catarina worked as a Modeler/Computational Chemist at BSIM Therapeutics. There, she contributed to the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidosis. She completed her PhD in computational biophysics at the University of Dundee.

Chris completed his PhD at the CCDC and the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci, and developed  the Fragment Hotspot Maps method.  Following this, Chris worked at the EMBL-EBI in the ChEMBL group,  incorporating target tractability information into Open Targets.

Daisuke has over 20 years' experience in drug discovery, including a postdoctoral placement at Harvard University with Professor Andrew Myers and management career at Sumitomo Dainippon Pharma. Daisuke heads our Japan office based in Osaka.

David joined Exscientia in 2019 from the SGC (Structural Genomics Consortium) where he worked as the Senior Informatician leading the development of novel informatics solutions.  Previously he worked in the lab of Professor Anne Dell working on software to automate the analysis of glycomics mass spectrometry experiments.  He completed his DPhil in Biochemistry at the University of Sussex.

Emil is a young addition to the company who brings a strong mathematical and computer science background. He pursued these fields from an early age and proved his competence by winning many awards such as the Golden Medal for the Romanian Maths Olympiad. Before joining Exscientia, he finished his Master’s Degree in Mathematics and Computer Science at the University of Oxford.

Eva joined Exscientia from the Research Data Management team at University of St Andrews where she worked as Data Scientist and Research Data Officer. She holds a PhD in Psychology and Neuroscience from the University of St Andrews and previously pursued four years' of postdoctoral research into neurodegenerative diseases at St Andrews and the University of Edinburgh before completing an MSc in Management and Information technology.

Frauke joined the Biophysical Drug Discovery Team at Exscientia after completing a PhD in Physical Chemistry at the ETH Zurich in Switzerland. She is experienced in method development in spectroscopy for structural biology applications. Her background is in Chemistry and she also enjoys programming. Prior to her PhD, she spent time as a research assistant at the University of Stuttgart in Germany and the University of Toronto in Canada. 

Garry joined Exscientia following an impactful career at AstraZeneca where he combined drug hunting and technology leadership.  In his role as Vice President of Hit Discovery and Chair of the Global Chemistry Leaders Network he led High throughput Screening, DNA Encoded Library screening and virtual screening, he was also responsible for many strategic initiatives; Garry championed AstraZeneca’s developments in artificial intelligence, machine learning and physics based computational methods, ultimately leading to AstraZeneca's “Augmented Drug Design” programme. He also established an automation facility in Gothenburg, dedicated to synthesis and integrated screening.   He has a passion for efficient drug discovery and constantly strives for new, innovative ways to drive projects forward to discover high quality candidates. Garry obtained his PhD in organic Chemistry from the University of Southampton. 

Heather has over 20 years' experience as a Clinical Monitor and Project Manager in Clinical Research Trials Phases I - IV. She began her career with five years at contract research organisation, Quintiles, before moving into mid-large pharma. She has overseen numerous global and mega trials at Schering Plough, MSD, Pfizer and Novartis, across a variety of therapy areas including CNS, women's health, oncology and cardiovascular.

Henry is strengthen our 3D structure team following a postdoctoral role at the Structural Genomics Consortium at the University of Oxford where he worked in the Membrane Protein Structure and Function group led by Dr Katharina Duerr with an emphasis of structural studies by cryo-EM. Prior t that he completed a PhD in Structural Enzymology with Prof Gideon Grogan at the University of York on a range of oxidoreductases, with structural studies reinforced by X-ray crystallography.

Iva is at the forefront of some of Exscientia’s most challenging and rewarding research, combining this role with her position as an Independent Investigator at the University of Dundee. Prior to joining, she served as Chief Scientific Officer at Kinetic Discovery and as Principal Scientist at Pfizer. She also completed a PhD in biochemistry at Masarykova Univerzita. 

John is an experienced full stack software developer. After gaining a double first from the University of Cambridge he has worked on many projects, from websites viewed by millions, to self-driving cars and fish counting AI. He is excited by the potential for ML to revolutionise drug discovery, biomedical research and is passionate about growing the ML community.

With a BSc in physics from the Warwick University and MSc in computer science from the University of Bristol, Jonathan brings extensive technical experience from over 10 years in senior technical roles, consulting on strategic data projects delivering significant improvements in capability for the UK and US governments. 

Katie joined the Pharmacology team at Exscientia after completing an early career industry fellowship at Bicycle Therapeutics in Cambridge where she carried out high-throughput screening of bicyclic peptide libraries. With a PhD in molecular biology and biochemistry from the University of Warwick, Katie is applying her experience to developing assays for high-interest membrane protein targets.

Following 10 years as a Senior Research Scientist at the University of Oxford, Louise now oversees Exscientia’s research into the structure, function and biochemical significance of proteins, helping us continue to push the boundaries of AI drug development. She completed a PhD in the genetic engineering of brewing yeast. 

Non-Executive Director (Board of Directors)

Marius is a part of the AI & Technology Team at Exscientia. Prior to joining, he spent half a year in the A* Star Research Institute in Singapore where he was working on keyphrase extraction and compression of large neural networks using reinforcement learning. He graduated from the University of Edinburgh with a first class degree in AI and Computer Science. His research work at the university was based around knowledge systems and theory repair algorithms. 

Executive Director Quantitative Pharmacology

Martin joins Exscientia as an experienced pharmacologist. After gaining a PhD in Pharmacy from the University of Nottingham, he  joined Sygnature Discovery in the biosciences department focusing on enzymology and biophysics. This was followed by a move to UCB Pharma where he worked in the structural biology and primary pharmacology groups, ultimately leading the internal molecular pharmacology team, covering a broad range of targets and modalities. 

Millie is a Communications Executive at Exscientia. Having previously managed the Oxford Office, Millie brings over a decade of experience in administration and management with her. She was previously Senior Manager at the Mofgord Group, in Oxford, and has a Bachelor in Liberal Arts and Sciences, Humanities and General Studies from Colégio São Jorge dos Ilhéus.

After a degree in Chemistry from Warwick, an MSc in Computational Chemistry from Cardiff and undertaking research for a PhD in Computational Crystallography also from Cardiff, Nathan worked in the pharmaceutical industry followed by six years working at ChEMBL in Hinxton as well as one year cutting his software development teeth at a startup based out of Sydney. 

Ola gained a 1st class AI and Computer Science degree at the University of Edinburgh. During her degree she found passion for Reinforcement Learning completing a summer research project at the California Institute of Technology and subsequently a half year project in the A*STAR Research Institute in Singapore. She brings key insights and expertise to apply Reinforcement Learning methods to drug discovery in the AI and Technology Team at Exscientia.

Olivier is a highly accomplished drug discoverer, with over 15 years’ experience gained in biotech, CRO, research institutes and academia. Prior to joining Exscientia he held a Team Leader position in medicinal chemistry at Evotec, managing research across a variety of disease areas. A medicinal chemist by training, Olivier obtained a PhD from Newcastle University on DNA damage response inhibitors in collaboration with KuDOS, and spent 6 years working on anticancer therapeutics at the ICR, London.

With experience of working at leading scientific research facilities all over the world, Patrick is responsible for overseeing some of Exscientia’s most exciting breakthroughs. Before joining the company, he served as a Postdoctoral Researcher at Diamond Light Source and as a Visiting Scientist at the Structural Genomics Consortium. He completed a PhD in structural biology at top Australian institution, Griffith University.

Patrizia joined Exscientia in 2019 having completed her PhD in biological sciences at Università di Pavia. She also spent time as a PhD Researcher at the Structural Genomics Consortium, a not-for-profit organisation that aims to catalyse research in new areas of human biology and drug discovery by focusing on less well-studied areas of the human genome.

Paul is working in the AI and Technology Team at Exscientia. Before joining he spent six months at a startup, working on the development of an autonomous wildfire detection and suppression system. He recently completed his PhD in computer science at the University of Liverpool, focusing on formal verification techniques for the analysis of Markov models.

Peter gained his PhD in organic chemistry with Stan Roberts at University of Liverpool followed by a postdoctoral and lectureship position with Gerry Pattenden at University of Nottingham. He then joined Incenta-Amura to develop cysteine protease inhibitors, followed by a decade at Organon, Schering-Plough and Merck(MSD) working as a project leader on CNS and CV therapeutic areas. This was followed by a Group leader position at UCB and then leading the University of Dundee Gates and Wellcome Trust funded TB research programs. 

Research Scientist, Biophysical Drug Discovery 

Philipp joined Exscientia from NZP-UK in Reading where he worked in the process development lab for the synthesis of bile acids. Prior to that he received his DPhil in organic chemistry at the University of Oxford under the supervision of Stephen P. Fletcher. During this course he investigated asymmetric syntheses of small building blocks found in natural products and natural product derivatives.

Senior Scientist, Head of GPCR Pharmacology

Reid is an expert in GPCR research where he has developed next-generation biosensors to interrogate nearly all GPCR signaling pathways in parallel with extremely high-fidelity. These tools enable direct, unbiased and automated analysis of ligand-receptor-transduction relationships. Reid trained under Prof Bryan Roth at the University of North Carolina.

Rob draws from experience working as a software and data engineer across a range of sectors including finance, advertising, security, and bioinformatics. He now pools that knowledge to find ways to maximise the scalability and performance of the infrastructure underpinning the Exscientia platform.

Ross gained a PhD in immunology at the University of York followed by a post doctorate at the London School of Hygiene & Tropical Medicine where he developed the first high-content image machine learning platform for drug discovery against neglected tropical diseases. This work resulted in the first new late-lead drug to fight schistosomiasis for several decades. Subsequently Ross led a team at UCB responsible for in vitro assay development and pharmacology for early and late stage drug discovery projects.  

Sean’s recent promotion to Senior Bioanalytical Scientist follows roles as a Bioanalytical Scientist at both Kinetic Discovery and Exscientia. Prior to that, he spent several years in academia, serving as Physical Sciences Teacher at St. Andrew's College and Chemistry Senior Tutor and Demonstrator at the Stellenbosch University. He completed his PhD in inorganic chemistry at the University of Oxford. 

After a career in research at the University of Dundee, first studying protein phosphorylation and then reproductive health, Senga moved into project management and administration covering multiple international projects.

Simon is Exscientia’s Senior Cloud Engineer, responsible for all cloud infrastructure and systems.  Prior to Exscientia, Simon spent a decade in System Administration and High Performance Computing roles for the Life Sciences department at the University of Dundee.  Simon gained a BSc Hons in Web Development at the University of Abertay Dundee.  

Simon is an experienced IT Professional, with previous roles within HE and Financial services. At Exscientia he supports the global user base whilst also building and developing infrastructure to support the company as it grows. Prior to working in IT, Simon graduated with a BA from the Academy of Contemporary Music.

As part of the Protein Science Group, Simon is tasked with conducting research into the structure, function and biochemical significance of proteins. Prior to joining the company, he held a similar role at Kinetic Discovery and served as a Postdoctoral Research Technician at the University of Edinburgh. He has a PhD in structural and molecular biology.

Simone has a wealth of scientific research experience, which he uses to help determine the structure of large biomolecules that provide crucial information in drug development. Prior to joining Exscientia, he served as a Senior Research Scientist at Kinetic Discovery and as a Postdoctoral Research Associate at Diamond Light Source. He completed a PhD in biochemistry at Universidad Autónoma de Madrid.

After finishing a degree in Business and Economics, Steve spent the early 2000’s in Local Authority IT developing and managing large complex environments before moving into the education sector with RM until 2012. From there he moved into the secure IT space, firstly with Sophos as their Global Infrastructure Architect leading multinational teams and company IT strategy and subsequently to Prolinx where he was Senior Solution Architect and Development Team Manager.

Vackar is a full-stack Software Engineer with a wealth of experience in both commercial and research environments . He spent over a decade leading development efforts of a number of high profile projects across various groups at the University of Dundee. He was trained in Physics and Applied Computing at the University of Dundee, specialising in Applied Computing. This was subsequently followed by a masters in Computer Science from Lancaster University. 

Prior to joining Exscientia, Víctor focused his research on applying computational and experimental techniques to advance drug discovery projects in infectious and neurodegenerative diseases. He completed his PhD in Medicinal Chemistry at the Complutense University of Madrid and the Spanish National Research Council receiving the PhD Award by Eli Lilly and the Spanish Royal Society of Chemistry. Víctor also developed his research at several institutions including the University of Cambridge. 

Willem gained a PhD in computational chemistry in the group of David Reinhoudt at the University of Twente followed by a post doctorate at Yale. He subsequently spent a decade at Pfizer focusing on computational techniques for HTS triage and combinatorial library design. This was followed by a position as Senior Solutions Consultant at Accelrys assisting a range of clients from small biotech to big pharma.  

Alan is a data engineer with a wealth of experience in delivering projects combining data architecture, analytics and database system engineering. Following an early career in geosciences, he focused on technology via an MSc. in Information Systems from the University of Edinburgh, followed by five years at Oracle. He continued his career as a database and analytics consultant across a range of industries, working with large corporate clients and small software houses, including several years in a proteomics research group at the University of Dundee.

Andrew graduated from the University of Edinburgh with an MA in Accounting & Finance. Before joining Exscientia, Andrew worked as an Associate Client Advisor at the financial firm Mazars where he specialised in working with a range of SMEs, helping them to grow and develop. 

Andrew is a Senior Biological Data Scientist within the Target Analysis team. He joined Exscientia from Immunocore, where he was a Senior Bioinformatician working on immune oncology and infectious disease programs. Prior to that, he gained a DPhil from Oxford University, where he used mathematical modelling and bioinformatics to analyse pathogen evolution and epidemiology.

Anna Lobley gained her PhD in Bioinformatics in the group of Professor David Jones, UCL predicting the functions of gene sequences. After spending a year in Geneva at Merck Serono, Anna joined the CRUK/Francis CRICK biostatistics and bioinformatics group focussing on cancer informatics, and acquiring expertise in Next Gen Sequencing across a range of biological domains. Anna joins us from Barts Cancer Institute and QMUL, where she collaborated with industrial and academic teams to create a multi-omics discovery platform for skin aging biology.

Dan obtained an MSci in Chemical Physics from the University of Bristol. During his undergraduate, he worked for Merck Chemicals Ltd. on a functional optical materials project and his master’s thesis involved characterising the suitability of nanoengineered stainless steels for next generation nuclear reactors. He has also worked for a biotechnology startup; Oxford Nanoimaging and has a deep passion for programming, particularly in Python.

Den’s PhD explored the role of insect innate immunity on River Blindness transmission at the Institute for Agricultural Research & Development in Cameroon and Keele University, followed by a postdoc in Andrew Knight’s lab at the University of Edinburgh. Den moved to industry in 2004 as a Product Manager at Lab901, a microfluids start-up. In 2010 she joined SULSA as Executive Director where she established new research collaborations and large public private partnerships such as the European Lead Factory and the National Phenotypic Screening Centre, where she was appointed Executive Director in 2015. 

Duncan is a full-stack Senior Software Engineer, with over a decade of experience of building large and robust commercial web applications. Previously, he has worked on numerous projects in the healthcare and legal tech industries. He gained his first-class degree in Applied Computing at the University of Dundee.

Research Scientist, Structural Bioinformatics 

Francesca joined the Structural Bioinformatics Team at Exscientia after completing her PhD at Imperial College London, where she focused on applying network science methods to develop efficient representations of protein structure and function. During her PhD, she also spent some time at MIT to study activation mechanisms in anti-apoptotic proteins.

Gabriel brings over 6 years of Automation and Sample Management experience to Exscientia previously worked for an Agricultural Research Company in the UK. He finished Biology BsC and Hydrology MsC at University of Debrecen (Hungary) focusing on water quality. Gabriel will be interacting with multi-disciplinary teams to maximise productivity and to ensure the rapid and efficient execution of research projects. 

Financial Planning & Analysis (FP&A) Manager

George is an experienced Finance professional, having previously led Financial Planning and Analysis at OXIS Energy. Prior to that, he worked as a Finance Business Partner on clinical trials at Summit Therapeutics, an AIM & NASDAQ listed Biotech developing innovative antibiotics. He also has a background in Chemistry having obtained a BSc degree in the subject from Nottingham Trent University.

Hanne is a Technical Project Manager in the Engineering team, using her experience as a Scrum Master and Agile Coach to create high performing teams and ensuring transparent communication of software development projects throughout Exscientia. She gained her knowledge from a number of technology companies in Edinburgh after completing her Master's degree in Speech and Language Processing at the University of Edinburgh.

Jieming is a full-stack Software Engineer with over 10 years experience focusing on cutting edge web technologies. Prior to joining Exscientia he was a Lead Engineer in Juralio Ltd., responsible for the development of their legal tech platform. Earlier, he worked at Citibank (Shanghai) as a Technical Project Manager focusing on developing the online banking system. Jieming was educated at The University of York and completed his MSc with Distinction in Software Engineering.   

Laura joined Excientia as a Drug Discovery Scientist after completing her Ph.D. in Infection and Immunology at the University of Liverpool, where she focused on progressing an immunotherapeutic peptide towards human trials through binding partner identification and mechanism of action studies. Laura is applying this experience to characterise target proteins and to design and validate targeted bioassays.

Liam gained a 1st class Bsc in Games Technology from the University of the West of England. He has since spent roughly a decade working at various software companies, eventually achieving the rank of Senior Software Engineer at Exscientia. At Exscientia, Liam is in charge of developing part of the in-house drug discovery automation platform, Centaur Biologist.

Lois completed her PhD in Organic Chemistry at the University of Cambridge in 2018, where she worked on antibiotic-autoinducer conjugates for use against antibiotic-resistant bacteria. After this, she worked as a Web Developer at Mirum Agency in Helsinki, before moving back to the UK and joining Exscientia as a Software Engineer.

Manisha is a highly accomplished drug discoverer, with over 20 years’ experience in medicinal chemistry, with a track record of delivering from the exploratory phase to the clinic. Working in various therapeutic areas, from neuroscience, endocrine, oncology and pain.  Prior to joining Exscientia she was a project leader at Eli Lilly working with different functions globally within DCRT that include pharmacology, pharmacokinetics and pharmaceutical sciences. Manisha obtained her PhD at the University of Nottingham and Postdoc experience at the ETH Zurich University.

Marco gained his PhD in medicinal chemistry from Cardiff University where he also was a post-doctoral researcher working on the development of novel antiviral agents. He then joined the Sussex Drug Discovery Centre working as a Project Leader across a number of research projects in the anticancer and CNS therapeutic areas.

Marie has more than 20 years of experience as a Cell Biologist gained in academia, CRO and drug discovery. Her previous roles include Senior Scientist at Sygnature Discovery where she supported integrated drug discovery projects within the inflammation, immuno-oncology and fibrosis areas as well as to establish 3D in vitro toxicology platforms and high content imaging capability to enable biological profiling of early stage drug candidates. Marie has a PhD from Sheffield University on Transglutaminase 2 mediated protein crosslinking in fibrosis with a focus on small molecule inhibition of fibrotic pathways in treating Chronic Kidney Disease and Diabetic Nephropathy. 

Mark gained a PhD in Biochemistry in the group Mike Fried at CRUK’s London Research Institute studying regulators of p53. A postdoctoral position in Pascal Meier’s Cell Death and Inflammation at the ICR was followed by a ten-year stint as a group leader at the MRC IGMM studying E3 ubiquitin ligases in development and tissue homeostasis. Inspired by the data revolution, he completed a Data Science MSc and joined Exscientia to apply his oncology and data science knowledge. 

Research Scientist, In-vitro Pharmacologist

Miriam gained her PhD in Cell and Molecular Biology at the University of Bologna in 2017. She then joined the Blaby’s group in the Biology Department of the Brookhaven National Laboratory in Long Island for a postdoc focused on the characterization of a large metallochaperone protein family. She is passionate about biochemistry, in particular about enzymatic spectrophotometric assays.

Prior to joining the computational drug designer team at Exscientia, Nanna was a medicinal chemist at Eli Lilly. There, she contributed to the advancement of several neuroscience projects and developed a strong interest in computational methods to support drug discovery. Nanna completed her PhD in organic chemistry and catalysis at Stockholm University, after which she was awarded a Marie-Curie postdoctoral fellowship to develop methods for C-H bond functionalisation at Queen Mary University of London and University of Manchester.

Before joining Exscientia, Piotr worked for three years at Selvita. He was responsible for the transfer, development, optimization, and validation of the cell-based assays. He gained an MSc degree in Medical Biotechnology from the Medical University of Silesia. During his master's course, he had a summer internship in the Department of Oncology at the University of Oxford and a half-year internship in the Dana-Farber Cancer Institute at the Harvard Medical School.

Richard has spent almost 20 years in drug discovery, first as a computational chemist, and then in business development. After his degree and PhD in Biochemistry & Molecular Biophysics at the University of Oxford, he spent several years working in academia, biotech and government labs in California as a comp chemist. In 2008 he was hired as the Head of Computational Chemistry at Evotec, and after leading a team and several drug discovery projects, became SVP Business Development, managing a team to build sucessful alliances between Evotec and biotech and Pharma.

Sarah works in the HR team at Exscientia as HR Operations Specialist. Prior to Exscientia she worked for a management consultancy in both the Talent Acquisition and HR Operations teams. Sarah has a keen interest in employee engagement and organisational culture and the vital role HR plays in both areas.

Executive Director Computational Drug Designer

Team

Board of Directors

JOIN US

We are a creative, passionate and collaborative organisation dedicated to settling bold new standards in drug discovery and design. If you have the ingenuity, energy and ambition to help us change the world, we would love to hear from you.